MET alterations in NSCLC-Current Perspectives and Future Challenges

Jordi Remon*, Lizza E L Hendriks, Giannis Mountzios, Rosario García-Campelo, Stephanie P L Saw, Dipesh Uprety, Gonzalo Recondo, Guillermo Villacampa, Martin Reck

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

738 Downloads (Pure)


Targeted therapies have revolutionized the treatment and improved the outcome for oncogene-driven NSCLC and an increasing number of oncogenic driver therapies have become available. For MET-dysregulated NSCLC (especially MET exon 14 skipping mutations and MET-amplifications, which is one of the most common bypass mechanisms of resistance in oncogene-addicted NSCLC), several anti-MET-targeted therapies have been approved recently (MET exon 14 skipping mutation) and multiple others are in development. In this narrative review, we summarize the role of MET as an oncogenic driver in NSCLC, discuss the different testing methods for exon 14 skipping mutations, gene amplification, and protein overexpression, and review the existing data and ongoing clinical trials regarding targeted therapies in MET-altered NSCLC. As immunotherapy with or without chemotherapy has become the standard of care for advanced NSCLC, immunotherapy data for MET-dysregulated NSCLC are put into perspective. Finally, we discuss future challenges in this rapidly evolving landscape.

Original languageEnglish
Pages (from-to)419-435
Number of pages17
JournalJournal of Thoracic Oncology
Issue number4
Early online date29 Oct 2022
Publication statusPublished - Apr 2023


Dive into the research topics of 'MET alterations in NSCLC-Current Perspectives and Future Challenges'. Together they form a unique fingerprint.

Cite this